6 recruiting, 3 active not recruiting, 1 completed, 1 enrolling by invitation. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Recruiting 6, Active not recruiting 3, Completed 1, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1 |
Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study) Intravitreal anti-VEGF injection, Faricimab - Diabetic Macular Edema | Phase 4 | Not yet recruiting | Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust | 120 | 2026-11-01 | 2026-08-07 |
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome Faricimab Injection [Vabysmo] - Presumed Ocular Histoplasmosis | Phase 4 | Recruiting | Cincinnati Eye Institute, Southwest Ohio | 25 | 2026-07-01 | 2026-07-10 |
| Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration | Phase 4 | Recruiting | Junyeop Lee | 64 | 2026-06-29 | 2026-07-27 |
| Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material Vabysmo 6 MG in 0.05 ML Injection - Macular Degeneration, Age Related | Phase 4 | Recruiting | Biobizkaia Health Research Institute | 100 | 2026-05-25 | 2026-05-28 |
| Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization | Phase 4 | Recruiting | Hospital Authority, Hong Kong | 40 | 2025-08-21 | 2025-10-01 |
| Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy | Phase 4 | Recruiting | Association for Innovation and Biomedical Research on Light and Image | 120 | 2025-08-06 | 2026-02-06 |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Faricimab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Active not recruiting | Hoffmann-La Roche | 274 | 2025-03-14 | 2026-10-27 |
| Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy Faricimab Injection, sham treatment - Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus | Phase 4 | Enrolling by invitation | University of Colorado, Denver | 100 | 2024-07-12 | 2026-06-01 |
| Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration Aflibercept 40 MG/ML, Faricimab 120 MG/ML - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Medical University of Graz | 70 | 2023-07-04 | 2025-06-06 |
| Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial Faricimab - Diabetic Macular Edema | Phase 4 | Active not recruiting | McMaster University | 446 | 2023-05-01 | 2026-04-17 |
| Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Faricimab Injection - Wet Age-related Macular Degeneration | Phase 4 | Recruiting | Faculty Hospital Kralovske Vinohrady | 100 | 2023-03-31 | 2025-03-13 |
| Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO] - Diabetic Macular Edema | Phase 4 | Unknown | Vista Klinik | 30 | 2022-11-01 | 2022-11-09 |
| A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema Faricimab - Diabetic Macular Edema | Phase 4 | Active not recruiting | Genentech, Inc. | 218 | 2022-02-28 | 2026-08-25 |
Macular Degeneration (2) · Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Glycogen Storage Disease Type II (1) · Polypoidal Choroidal Vasculopathy (1)
Association for Innovation and Biomedical Research on Light and Image (1) · Biobizkaia Health Research Institute (1) · Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust (1) · Cincinnati Eye Institute, Southwest Ohio (1) · Faculty Hospital Kralovske Vinohrady (1) · Genentech, Inc. (1) · Hoffmann-La Roche (1) · Hospital Authority, Hong Kong (1) · Junyeop Lee (1) · McMaster University (1) · Medical University of Graz (1) · University of Colorado, Denver (1) · Vista Klinik (1)
United States (5) · Spain (3) · United Kingdom (3) · Australia (2) · Canada (2) · Italy (2) · South Korea (2) · Austria (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Kenya (1)
Andreas Wedrich, MD (1) · Bushra Mushtaq, FRCS (1) · Dr. Varun Chaudhary, MD, FRCS(C) (1) · Junyeop Lee, PhD (1) · Katja Hatz, MD (1) · Martin Pencak, MD (1)
2023 (1)